Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors

Thyroid

Volumn 24, Issue 2, 2014, Pages 277-286

  Cho, Sun Wook ^a   Choi, Hoon Sung ^a   Yeom, Gye Jeong ^a   Lim, Jung Ah ^a   Moon, Jae Hoon ^b   Park, Do Joon ^a   Chung, June Key ^a   Cho, Bo Youn ^c   Yi, Ka Hee ^a   Park, Young Joo ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84894118261     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0654     Document Type: Article

References (46)

1. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F 1984 Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 53:982-992.
2. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA 1988 Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508.
3. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL 1984 Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57:323-327.
4. Casara D, Rubello D, Saladini G, Gallo V, Masarotto G, Busnardo B 1991 Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori 77:432-436.
5. Samaan NA, Schultz PN, Haynie TP, Ordonez NG 1985 Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60:376-380.
6. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242.
7. Lang BH, Wong KP, Cheung CY, Wan KY, Lo CY 2013 Evaluating the prognostic factors associated with cancerspecific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann Surg Oncol 20:1329-1335.
8. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605.
9. Mihailovic J, Stefanovic L, Malesevic M, Markoski B 2009 The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Thyroid 19:227-232.
10. Lee J, Soh EY 2010 Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann Surg 251:114-119.
11. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899.
12. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR 2003 Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191-197.
13. Benbassat CA, Mechlis-Frish S, Hirsch D 2006 Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 30:1088-1095.
14. Huang IC, Chou FF, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh CJ, Wang PW 2012 Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. Clin Endocrinol 76:439-447.
15. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626-1631.
16. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110:1451-1456.
17. Olaleye O, Ekrikpo U, Moorthy R, Lyne O, Wiseberg J, Black M, Mitchell D 2011 Increasing incidence of differentiated thyroid cancer in South East England: 1987-2006. Eur Arch Otorhinolaryngol 268:899-906.
18. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
19. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW 2005 Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol 62:156-162.
20. Hayashi Y, Lagarde F, Tsuda N, Funamoto S, Preston DL, Koyama K, Mabuchi K, Ron E, Kodama K, Tokuoka S 2010 Papillary microcarcinoma of the thyroid among atomic bomb survivors: tumor characteristics and radiation risk. Cancer 116:1646-1655.
21. Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV 2009 Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19:333-340.
22. Rumyantsev PO, Saenko VA, Ilyin AA, Stepanenko VF, Rumyantseva UV, Abrosimov AY, Lushnikov EF, Rogounovitch TI, Shibata Y, Mitsutake N, Tsyb AF, Yamashita S 2011 Radiation exposure does not significantly contribute to the risk of recurrence of Chernobyl thyroid cancer. J Clin Endocrinol Metab 96:385-393.
23. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, Lee JS 2012 Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 44:11-24.
24. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525-531.
25. Park YJ, Ahn HY, Choi HS, Kim KW, Park Do J, Cho BY 2012 The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid 22:356-362.
26. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93:4683-4689.
27. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park Do J, Cho BY 2006 Analysis of differential BRAF (V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107:1831-1838.
28. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park Do J 2012 The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773.
29. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670.
30. Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S 2011 Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J 58:381-393.
31. Kim JY, Moon SJ, Kim KR, Sohn CY, Oh JJ 1998 Dietary iodine intake and urinary iodine excretion in normal Korean adults. Yonsei Med J 39:355-362.
32. Cho BY, Choi H, Park YJ, Lim JA, Ahn HY, Lee EK, Kim KW, Yi KH, Chung JK, Youn YK, Cho NH, Park DJ, Koh CS 2013 Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past 4 decades. Thyroid 23:797-804.
33. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, Ventroni G, Antonaci A, Vestri AR 2004 Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging 48:12-19.
34. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW, Chen JY, Li KL, Chen JF, Ho YS 1999 Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 9:1227-1235.
35. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Pagetta C, Gross MD, Al-Nahhas A, Rubello D 2007 Papillary thyroid PROGNOSIS OF DTC LUNG METASTASIS 285 carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 32:440-444.
36. Sisson JC, Giordano TJ, Jamadar DA, Kazerooni EA, Shapiro B, Gross MD, Zempel SA, Spaulding SA 1996 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 78:2184-2192.
37. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80:2041-2045.
38. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC 2001 Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627-5632.
39. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M 1999 Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443-457.
40. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM 2000 Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21:1271-1279.
41. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M 2004 Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 27:334-339.
42. Fernandez CA, Puig-Domingo M, Lomena F, Estorch M, Camacho Marti V, Bittini AL, Marazuela M, Santamaria J, Castro J, Martinez De Icaya P, Moraga I, Martin T, Megia A, Porta M, Mauricio D, Halperin I 2009 Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest 32:228-233.
43. Courbon F, Zerdoud S, Bastie D, Archambaud F, Hoff M, Eche N, Berry I, Caron P 2006 Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 16:1025-1031.
44. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623-632.
45. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrump DS, Libutti SK, Alexander HR Jr, Sarlis NJ 2003 Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol 82:10-18.
46. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol 63:418-427.